Shougang LanzaTech Surges Over 40% on Second Trading Day, More Than Doubling From IPO Price
Taylor Wilson
Shougang LanzaTech surged over 45% on its second day of trading to HK$30.66, more than doubling from its HK$14.60 IPO price — fueled by a staggering 1,421x retail oversubscription and its status as the world's largest CCUS synbio company.
Two days, a double — how hot is this IPO?
Shougang LanzaTech (首钢朗泽) priced its IPO at HK$14.60. By day two it hit HK$30.66 — up over 45% on the session, more than doubling from the offer price.
Retail tranche oversubscription hit 1,421.54x. This means → for every share available to retail investors, more than 1,400 people were bidding.
In plain terms = this wasn't "some interest." It was a stampede at the gate, and the post-listing surge is the overflow money chasing what it couldn't get in the IPO.
What does the company actually do?
Shougang LanzaTech's core business is CCUS — carbon capture, utilization, and storage — turning carbon-rich industrial waste gas into useful products.
The method: take off-gas from steel and ferroalloy plants, then use synthetic biology — engineered microbes that literally "eat" the waste gas — to produce ethanol and microbial protein.
The company runs four commercial-scale plants in Hebei, Ningxia, and Guizhou, with combined annual capacity of 210,000 tonnes of ethanol and 23,200 tonnes of microbial protein.
Per Frost & Sullivan (2025 data), Shougang LanzaTech is the largest company globally in the synbio-based CCUS sector. This reflects not a concept-stage story but a proven production leader.
Where is the technical moat?
Guotou Securities International notes the company has built an end-to-end R&D platform spanning strain selection through industrial deployment. In plain terms = it controls the whole chain, from which microbes to breed to how the factory runs.
The technology has upgraded from first-generation carbon-reduction to second-generation carbon-negative processes. This means → it doesn't just emit less carbon — it achieves net carbon removal, which carries higher carbon-credit value.
The low-carbon profile has helped build a stable global customer base, with both the ethanol and microbial protein lines already fully commercialized.
Can the premium hold — and where is the risk?
The market's case for the premium rests on two pillars: scale leadership and an evolving technology roadmap.
The key test ahead: whether capacity advantage translates into sustained profitability. This means → the current price already embeds "biggest" and "most advanced" — earnings now need to follow.
In plain terms = the market bought the story first; the bill goes to the income statement.
Content is for reference only, not financial advice.